scholarly journals Tobacco and cannabis co-use: Drug substitution, quit interest, and cessation preferences.

2019 ◽  
Vol 27 (3) ◽  
pp. 265-275 ◽  
Author(s):  
Erin A. McClure ◽  
Rachel L. Tomko ◽  
Claudia A. Salazar ◽  
Saima A. Akbar ◽  
Lindsay M. Squeglia ◽  
...  
Keyword(s):  
Author(s):  
Athar Parvez Ansari ◽  
Sumyyah Hasina Sana ◽  
Mohammad Younis Dar ◽  
Pankaj Goswami ◽  
N. Zaheer Ahmed

Abstract Objectives To validate the concept of abadāl-i-adwiya (drug substitution) by evaluation of physicochemical standardization and hepatoprotective activity of Aristolochia rotunda & its substitute, Curcuma Zedoaria in albino Wistar rats. Methods Physicochemical standardization by estimation of moisture content, ash values and extractive values were carried out using standard methods. Hepatotoxicity was induced in albino Wistar rats using CCl4 1 mL/kg s. c. on alternate day for 14 days. Group I was served as Plain control and Group II as Negative control. Group III was administered silymarin 50 mg/kg p. o. while Group IV received HAE of A. rotunda 89.64 mg/kg p. o., and Group V was administered HAE of C. Zedoaria 45.73 mg/kg p. o. At the end of the study, serum bilirubin, AST (SGOT), ALT (SGPT) and ALP were estimated. The histopathology of liver was also carried out. Results The physicochemical parameters of both test drugs viz. moisture content, total ash, acid insoluble ash and water soluble ash were found within normal limit. The total serum bilirubin, direct bilirubin, AST (SGOT), ALT (SGPT) levels were significantly decreased in Test groups A and B when compared to the Negative and Standard controls. The microscopic examination of liver collected from animals of Group IV and Group V revealed significant recovery from hepatic toxicity compared to the Negative control. Conclusions The study experimentation has revealed that C. Zedoaria may be used as a substitute for A. rotunda in the treatment of liver diseases. However, the outcome has to be further corroborated with phytochemical evaluation and clinical trials of both the drugs. Furthermore, the concept of drug substitute in Unani system of medicine is also validated in the light of above study.


JAMA ◽  
1979 ◽  
Vol 242 (10) ◽  
pp. 1031-1032
Author(s):  
K. L. Beers
Keyword(s):  

2002 ◽  
Vol 32 (2) ◽  
pp. 503-522 ◽  
Author(s):  
Ralf Gerlach

Within a global context, Germany was relatively late in its acceptance of substitution treatment, having first introduced methadone maintenance treatment (MMT) in the late 1980s. Since the early 1990s, Germany has taken a number of legal steps which favor harm reduction, assistance and treatment, rather than the law enforcement approach that was dominant before. As a result of this new commitment, Germany now also allows the use of non-methadone substitutes, such as buprenorphine, LAAM, dihydrocodeine (DHC) and codeine. A heroin maintenance trial has been scheduled to begin in early 2002. Despite the fact that the overall number of participants in drug-substitution treatment has risen over the past decade from about 1,000 in the early 1990s to more than 55,000 in 2001 and that MMT has been comprehensively evaluated in Germany with favorable outcomes, there remains a lack of availability of and accessibility to substitution treatment, due to rigid entry and treatment criteria imposed by the social health insurers (SHI).


Neurology ◽  
1990 ◽  
Vol 40 (2) ◽  
pp. 386-386
Author(s):  
C. C. Peck, MD

Sign in / Sign up

Export Citation Format

Share Document